Eventide Asset Management RPRX Position
ActiveEventide Asset Management increased their position in Royalty Pharma plc (RPRX) in Q4 2025, holding $50.2M worth of shares across 1,296,826 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Full company profile →Short Interest
2.8%
3.6 days to cover
Eventide Asset Management RPRX Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Increased | 1,296,826 | +380,337 | $50.2M |
| Q3 2025 | Decreased | 916,489 | -5,150 | $32.3M |
| Q2 2025 | Increased | 921,639 | +41,830 | $33.4M |
| Q1 2025 | Increased | 879,809 | +56,419 | $27.4M |
| Q4 2024 | Increased | 823,390 | +50,767 | $21.0M |
| Q3 2024 | Increased | 772,623 | +22,993 | $21.9M |
| Q2 2024 | Increased | 749,630 | +58,943 | $19.8M |
| Q1 2024 | Increased | 690,687 | +156,712 | $21.0M |
| Q4 2023 | Decreased | 533,975 | -470,171 | $15.0M |
| Q3 2023 | Decreased | 1,004,146 | -35,572 | $27.3M |
| Q2 2023 | Decreased | 1,039,718 | -9,395 | $32.0M |
| Q1 2023 | New | 1,049,113 | +1,049,113 | $37.8M |
Frequently Asked Questions
Does Eventide Asset Management own RPRX?
Yes. As of Q4 2025, Eventide Asset Management holds 1,296,826 shares of Royalty Pharma plc (RPRX) valued at $50.2M. This data comes from their SEC 13F filing.
How many hedge funds own RPRX?
1 specialist biotech hedge fund currently holds RPRX. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy RPRX?
Eventide Asset Management's position in RPRX was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's RPRX position increasing or decreasing?
Eventide Asset Management increased their RPRX position in the most recent quarter, adding 380,337 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
RPRXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →